Imatinib as a Dominant Therapeutic Strategy in the Treatment of Chronic Myelogenous Leukemia: A Decision-Analytic Approach
Class of 2004 Abstract === Objective: To develop and populate a decision-analytic model comparing the cost and efficacy of imatinib versus allogenic bone marrow transplantation (BMT) with a matched unrelated donor in the treatment of newly-diagnosed, Philadelphia positive (Ph (+)), chronic phase, ch...
Main Author: | Ballard, Erin Elissa |
---|---|
Other Authors: | Skrepnek, Grant |
Language: | en_US |
Published: |
The University of Arizona.
2004
|
Subjects: | |
Online Access: | http://hdl.handle.net/10150/624778 http://arizona.openrepository.com/arizona/handle/10150/624778 |
Similar Items
-
TREATMENT WITH IMATINIB MESILAT IN CHRONIC MYELOGENOUS LEUKEMIA – OUR EXPERIENCE
by: Mateja Grat, et al.
Published: (2004-12-01) -
The treatment of pediatric chronic myelogenous leukemia in the imatinib era
by: Jae Wook Lee, et al.
Published: (2011-03-01) -
Efficacy of imatinib mesylate-based front-line therapy in pediatric chronic myelogenous leukemia
by: Hyun Jin Oh, et al.
Published: (2013-08-01) -
Chronic lymphocytic leukemia developing in a case of chronic myelogenous leukemia - accelerated phase: A rare case with review of the literature
by: Narender Kumar, et al.
Published: (2013-01-01) -
Imatinib Therapy in Chronic Myelogenous Leukemia and Thyroid Function Tests
by: Mohammad Ali Mashhadi, et al.
Published: (2014-09-01)